All In Biotech

Drug Trial Radar · NCT06383403

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

A Phase IIIb Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Effect of Elafibranor 80 mg on Normalisation of Alkaline Phosphatase in Adult Participants With Primary Biliary Cholangitis (PBC) and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

92

Actual

Start

Jul 9, 2024

Primary completion

Jun 16, 2026

Study completion Jun 16, 2026

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease. Primary biliary cholangitis is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). The main aim of this study is to determine if elafibranor is better than placebo in reducing ALP levels to a normal value. High ALP levels in the blood can indicate liver disease. There will be three periods in this study: A screening period (up to 8 weeks) to assess whether the participant can take part; a treatment period (up to 52 weeks) where eligible participants will be grouped as per their blood ALP levels and randomly assigned to either receive elafibranor or placebo, and a follow-up period (4 weeks) where participants' health will be monitored. Participants will be twice as likely to receive elafibranor than placebo (2:1 ratio). Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a noninvasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (a noninvasive test that passes a probe on skin to measure stiffness of the liver). They will also be asked to fill in questionnaires. Each participant will be in this study for up to 64 weeks (15 months).

Conditions

  • Primary Biliary Cholangitis

Interventions

  • ElafibranorDrug

    Round and orange film coated tablet of 80 mg.

  • PlaceboOther

    Round and orange film coated tablet of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with normalisation of Alkaline Phosphate (ALP) LevelsTime frame: At Week 52

Locations

60 sites in 10 countries. Site status is shown where the registry gives one.

  • Southern California Research Center

    Coronado, California

  • Topgraphy Health, Inc.

    Los Angeles, California

  • University of California, Davis

    Sacramento, California

  • Stanford University Medical Center

    Stanford, California

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • Rocky Mountain Gastroenterology

    Littleton, Colorado

  • International Center for Research

    Tampa, Florida

  • Delta Research Partners, LLC

    West Monroe, Louisiana

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Huron Gastroenterology Associates - Center for Digestive Care

    Ypsilanti, Michigan

  • South Denver Gastroenterology,P.C.

    Englewood, New Jersey

  • Southwest Gastroenterology Associates, PC (SWGA)

    Albuquerque, New Mexico

  • Northwell Health Center for Liver Disease and Transplantation

    Manhasset, New York

  • Charlotte Gastroenterology & Hepatology, PLLC

    Charlotte, North Carolina

  • Coastal Research Institute

    Fayetteville, North Carolina

  • Gastroenterology Center of the Midsouth

    Cordova, Tennessee

  • Methodist Transplant Physicians

    Dallas, Texas

  • American Research Corporation at The Texas Liver Institute

    San Antonio, Texas

  • American Research Corporation

    San Antonio, Texas

  • Velocity Liver Institute NW

    Seattle, Washington

  • Hepato-Gastroenterologie HK, s.r.o.

    Hradec Králové, Czechia

  • Artroscan

    Ostrava, Czechia

  • Research Site s.r.o.

    Pilsen, Czechia

  • Institute for Clinical and Experimental Medicine - IKEM

    Prague, Czechia

  • Clinique Pasteur

    Toulouse, France

  • Universitatsklinikum Heidelberg

    Heidelberg, Germany

  • Gastroenterologsiche Studiengesellschaft Herne

    Hemer, Germany

  • EUGASTRO GmbH

    Leipzig, Germany

  • Universitaetsklinikum Muenster

    Münster, Germany

  • Ospedale Policlinico San Martino - IRCCS

    Genova, Italy

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

    Palermo, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

  • IRCCS Istituto clinico humanitas - Humanitas Mirasole spa

    Rozzano, Italy

  • Krakowskie Centrum Medyczne Sp.z.o.o - FutureMeds

    Krakow, Poland

  • FutureMeds Warszawa Centrum

    Warsaw, Poland

  • Cluj County Clinical Emergency Hospital

    Cluj-Napoca, Romania

  • Gastromedica Srl

    Iași, Romania

  • Korea University Ansan Hospital

    Ansan-si, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • Kyungpook National University Hospital (KNUH)

    Daegu, South Korea

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.